158 related articles for article (PubMed ID: 26125948)
1. Discovery of CREBBP Bromodomain Inhibitors by High-Throughput Docking and Hit Optimization Guided by Molecular Dynamics.
Xu M; Unzue A; Dong J; Spiliotopoulos D; Nevado C; Caflisch A
J Med Chem; 2016 Feb; 59(4):1340-9. PubMed ID: 26125948
[TBL] [Abstract][Full Text] [Related]
2. Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain.
Unzue A; Xu M; Dong J; Wiedmer L; Spiliotopoulos D; Caflisch A; Nevado C
J Med Chem; 2016 Feb; 59(4):1350-6. PubMed ID: 26043365
[TBL] [Abstract][Full Text] [Related]
3. Fragment-based in silico screening of bromodomain ligands.
Spiliotopoulos D; Caflisch A
Drug Discov Today Technol; 2016 Mar; 19():81-90. PubMed ID: 27769362
[TBL] [Abstract][Full Text] [Related]
4. Structural dynamics and quantum mechanical aspects of shikonin derivatives as CREBBP bromodomain inhibitors.
Mitra S; Dash R
J Mol Graph Model; 2018 Aug; 83():42-52. PubMed ID: 29758466
[TBL] [Abstract][Full Text] [Related]
5. Virtual screen to NMR (VS2NMR): Discovery of fragment hits for the CBP bromodomain.
Spiliotopoulos D; Zhu J; Wamhoff EC; Deerain N; Marchand JR; Aretz J; Rademacher C; Caflisch A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2472-2478. PubMed ID: 28410781
[TBL] [Abstract][Full Text] [Related]
6. Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking.
Zhao H; Gartenmann L; Dong J; Spiliotopoulos D; Caflisch A
Bioorg Med Chem Lett; 2014 Jun; 24(11):2493-6. PubMed ID: 24767840
[TBL] [Abstract][Full Text] [Related]
7. Controlling Intramolecular Interactions in the Design of Selective, High-Affinity Ligands for the CREBBP Bromodomain.
Brand M; Clayton J; Moroglu M; Schiedel M; Picaud S; Bluck JP; Skwarska A; Bolland H; Chan AKN; Laurin CMC; Scorah AR; See L; Rooney TPC; Andrews KH; Fedorov O; Perell G; Kalra P; Vinh KB; Cortopassi WA; Heitel P; Christensen KE; Cooper RI; Paton RS; Pomerantz WCK; Biggin PC; Hammond EM; Filippakopoulos P; Conway SJ
J Med Chem; 2021 Jul; 64(14):10102-10123. PubMed ID: 34255515
[TBL] [Abstract][Full Text] [Related]
8. In silico quest of selective naphthyl-based CREBBP bromodomain inhibitor.
Dash R; Mitra S; Arifuzzaman M; Zahid Hosen SM
In Silico Pharmacol; 2018; 6(1):1. PubMed ID: 30607314
[TBL] [Abstract][Full Text] [Related]
9. Selective Fragments for the CREBBP Bromodomain Identified from an Encoded Self-assembly Chemical Library.
Catalano M; Moroglu M; Balbi P; Mazzieri F; Clayton J; Andrews KH; Bigatti M; Scheuermann J; Conway SJ; Neri D
ChemMedChem; 2020 Sep; 15(18):1752-1756. PubMed ID: 32686307
[TBL] [Abstract][Full Text] [Related]
10. Discovery of BAZ2A bromodomain ligands.
Spiliotopoulos D; Wamhoff EC; Lolli G; Rademacher C; Caflisch A
Eur J Med Chem; 2017 Oct; 139():564-572. PubMed ID: 28837921
[TBL] [Abstract][Full Text] [Related]
11. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
12. The "Gatekeeper" Residue Influences the Mode of Binding of Acetyl Indoles to Bromodomains.
Unzue A; Zhao H; Lolli G; Dong J; Zhu J; Zechner M; Dolbois A; Caflisch A; Nevado C
J Med Chem; 2016 Apr; 59(7):3087-97. PubMed ID: 26982797
[TBL] [Abstract][Full Text] [Related]
13. Molecular dynamics in drug design.
Zhao H; Caflisch A
Eur J Med Chem; 2015 Feb; 91():4-14. PubMed ID: 25108504
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.
Ghosh S; Taylor A; Chin M; Huang HR; Conery AR; Mertz JA; Salmeron A; Dakle PJ; Mele D; Cote A; Jayaram H; Setser JW; Poy F; Hatzivassiliou G; DeAlmeida-Nagata D; Sandy P; Hatton C; Romero FA; Chiang E; Reimer T; Crawford T; Pardo E; Watson VG; Tsui V; Cochran AG; Zawadzke L; Harmange JC; Audia JE; Bryant BM; Cummings RT; Magnuson SR; Grogan JL; Bellon SF; Albrecht BK; Sims RJ; Lora JM
J Biol Chem; 2016 Jun; 291(25):13014-27. PubMed ID: 27056325
[TBL] [Abstract][Full Text] [Related]
15. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains.
Hay DA; Fedorov O; Martin S; Singleton DC; Tallant C; Wells C; Picaud S; Philpott M; Monteiro OP; Rogers CM; Conway SJ; Rooney TP; Tumber A; Yapp C; Filippakopoulos P; Bunnage ME; Müller S; Knapp S; Schofield CJ; Brennan PE
J Am Chem Soc; 2014 Jul; 136(26):9308-19. PubMed ID: 24946055
[TBL] [Abstract][Full Text] [Related]
16. Discovery of selective inhibitors for cyclic AMP response element-binding protein: a combined ligand and structure-based resources pipeline.
Muneer I; Ul Qamar MT; Tusleem K; Abdul Rauf S; Hussain HMJ; Siddiqi AR
Anticancer Drugs; 2019 Apr; 30(4):363-373. PubMed ID: 30499778
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands.
Jennings LE; Measures AR; Wilson BG; Conway SJ
Future Med Chem; 2014 Feb; 6(2):179-204. PubMed ID: 24467243
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Identification of Inhibitory Fragments Targeting the p300/CBP-Associated Factor Bromodomain.
Chaikuad A; Lang S; Brennan PE; Temperini C; Fedorov O; Hollander J; Nachane R; Abell C; Müller S; Siegal G; Knapp S
J Med Chem; 2016 Feb; 59(4):1648-53. PubMed ID: 26731131
[TBL] [Abstract][Full Text] [Related]
19. Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities.
Chekler EL; Pellegrino JA; Lanz TA; Denny RA; Flick AC; Coe J; Langille J; Basak A; Liu S; Stock IA; Sahasrabudhe P; Bonin PD; Lee K; Pletcher MT; Jones LH
Chem Biol; 2015 Dec; 22(12):1588-96. PubMed ID: 26670081
[TBL] [Abstract][Full Text] [Related]
20. In silico fragment-based drug design with SEED.
Marchand JR; Caflisch A
Eur J Med Chem; 2018 Aug; 156():907-917. PubMed ID: 30064119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
